NF2 and neoplasm: Deletions, nonsense mutations, splice site mutations, and translocations in NF2/Merlin are identified in 50–60% of the general population of patients with meningiomas, and loss of chromosome 22 in tumor tissue can be seen in 40–80% of patients developing meningioma [23,24].